Lonza Bend (US) upgrades capabilities in early phase clinical manufacturing services with the addition of bottling and labeling equipment
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
BAV has revolutionized the animal vaccination industry with its ground-breaking delivery methods that prioritize quality, safety, and efficacy
Reported profit after tax declined 19% year-on-year to Rs 76 crores
Acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret
The My Green Lab Certification is the gold standard for laboratory sustainability practices worldwide
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
Abdel has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma,
Subscribe To Our Newsletter & Stay Updated
